Evidence map›Paper›PMID 24317131›Full record

ArticleBone marrow transplantation2014

Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

E de Berranger, A Cousien, A Petit, R Peffault de Latour, C Galambrun, Y Bertrand, A Salmon, F Rialland, P-S Rohrlich, J-P Vannier and 6 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02670252 (Busulfan Plus Cyclophosphamide vs Total Body Irradiation Plus Cyclophosphamide Conditioning Regimen for Standard-risk Acute Lymphocytic Leukemia Undergoing HLA-matched Allogeneic Hematopoietic Stem Cell Transplantation), which is not on this map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02670252 phase3completednot on this mapstarted 2016, after this paper: background citation

Busulfan Plus Cyclophosphamide vs Total Body Irradiation Plus Cyclophosphamide Conditioning Regimen for Standard-risk Acute Lymphocytic Leukemia Undergoing HLA-matched Allogeneic Hematopoietic Stem Cell Transplantation

TypeinterventionalSponsorNanfang Hospital, Southern Medical UniversityRan2016 to 2022Enrolled550ConditionsAllogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Total Body Irradiation, Acute Lymphocytic LeukemiaArmsBusulfan (BU), Cyclophosphamide (CY), Total Body Irradiation (TBI)
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 11 institutions in 1 country.

E de BerrangerPediatric Hematology Department, Jeanne de Flandre Hospital, CHRU Lille, Lille, France.
A CousienEA 2694, Faculté de Médecine, Lille, France.
A PetitPediatric Hematology and Oncology Department, Trousseau Hospital, Assistance Publique-Hopitaux de Paris, Paris, France.
R Peffault de LatourHematology Department, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
C GalambrunPediatric Hematology Department, Timone Hospital, Marseille, France.
Y BertrandPediatric Hematology and Oncology Unit, IHOP, Lyon, France.
A SalmonPediatric Hematology and Oncology Department, CHU Nancy, Vandoeuvre-les-Nancy, France.
F Rialland1] Centre Hospitalier et Universitaire (CHU) de Nantes, Service d'Onco-Hématologie Pédiatrique, Nantes, France [2] Université de Nantes, Faculté de Médecine, Nantes, France.
P-S RohrlichHSCT department, CHU Besançon, Besançon, France.
J-P VannierPediatric Hematology and Oncology Unit, CHU Rouen, Rouen, France.
P LutzPediatric Hematology and Oncology Unit, CHU Strasbourg, Strasbourg, France.
K YakoubenPediatric Hematology Department, Robert Debré Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
A DuhamelEA 2694, Faculté de Médecine, Lille, France.
B BrunoPediatric Hematology Department, Jeanne de Flandre Hospital, CHRU Lille, Lille, France.
G MichelPediatric Hematology Department, Timone Hospital, Marseille, France.
J-H Dalle1] Pediatric Hematology Department, Robert Debré Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France [2] INSERM 1149, Paris Diderot University, Paris, France.
Hôpital de la Timone · FRHôpital Jeanne de Flandre · FRHôpital Robert-Debré · FRUniversité de Lille · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Régional et Universitaire de Nancy · FRCentre Hospitalier Universitaire de Besançon · FRCentre Hospitalier Universitaire de Nantes · FRCentre Hospitalier Universitaire de Rouen · FRHôpital Saint-Louis · FRInstitut d’Hématologie et d’Oncologie Pédiatrique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic SCT (HSCT) appears to be an efficient tool to cure high-risk AML in first CR but the choice between BU-based or TBI-based conditioning regimens still remains controversial. In order to analyze the impact of conditioning regimen on long-term survival, we conducted a retrospective analysis from French registry data including all consecutive patients under 18 years old (n=226) from 1980 to 2004 transplanted for AML in CR1 from sibling (n=142) or matched unrelated donors and given either TBI-1200 cGy and CY 120 mg/kg (TBI-Cy, n=84) or BU 16 mg/kg and CY 200 mg/kg (BuCy200, n=142). Patient subgroups were comparable for all criteria except for median age at diagnosis and HSCT and for donor type. Both 5-year OS and disease-free survival (DFS) were significantly better in BuCy200 group (P=0.02 and 0.005, respectively). In multivariate analysis, both HLA matching and BuCy200 appeared as good prognostic factors for treatment-related mortality and DFS. Grade 2-4 acute GvHD and chronic GvHD rates were statistically higher in TBI-Cy group than in Bu-Cy200 one with a RR at 2 (P=0.002). In total, Bu-Cy200 conditioning regimen gives better outcome compared with TBI-Cy irrespective of the stem cell source and the donor type.

Indexed as

Hematopoietic Stem Cell TransplantationAdolescentBody WeightBusulfanChildChild, PreschoolCyclophosphamideFemaleFranceGraft vs Host DiseaseHumansInfantKaplan-Meier EstimateLeukemia, Myeloid, AcuteMaleMultivariate AnalysisBusulfanCyclophosphamide

Identifiers

PMID24317131
OpenAlexW2327203955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.